Company intelligence / Profile preview

Kos Pharmaceuticals, Inc.

Cranbury, New Jersey, United Statessec.gov ↗

Ownership: Private
Employees: ~726
Development stage: Commercial

Overview

Kos Pharmaceuticals specialized in reformulating existing FDA-approved medications to improve safety, effectiveness, and ease of use. The company marketed cholesterol modulation products Niaspan and Advicor, as well as Azmacort Inhalation Aerosol for asthma treatment.

Therapeutic areas: PulmonologyCardiovascular
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

5 assets

niacin

Commercial

Indications: hypercholesterolemia, severe hypertriglyceridemia (SHTG), hypertriglyceridemia, mixed dyslipidemia, Hypercholesterolemia

4 more assets in the full pipeline.

Request access →

Partnerships

Knoll PharmaceuticalsDuPontMerck KGaAOryxTakedaAventis

Beyond the preview

Go deeper on Kos Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kos Pharmaceuticals, Inc..

Explore the full profile